Gradalis
Gradalis is a biotechnology company focused on developing Vigil, a personalized cancer immunotherapy, with applications in ovarian and other solid tumor cancers.
About Gradalis
Gradalis is a biotechnology company focused on developing personalized cancer immunotherapies. Located at 2545 Golden Bear Drive, Suite 110, Carrollton, TX 75006, the company aims to harness the power of the body's immune system to combat cancer. Their primary product, Vigil, represents an innovative approach to cancer treatment by tailoring therapy to the individual patient.
Cancer Prevention and Research Institute of Texas Grant
Gradalis has been awarded a $9.9 million grant from the Cancer Prevention and Research Institute of Texas. This significant funding supports the development and clinical trials of their personalized cancer immunotherapy, Vigil. The grant underscores the potential impact of Gradalis' work in the field of cancer treatment.
Vigil Cancer Immunotherapy
Vigil is Gradalis' flagship product, a fully personalized, patient-specific cancer immunotherapy. Utilizing a proprietary gene plasmid, Vigil involves the genetic modification of a patient's cancer cells to stimulate an immune response. Currently, Vigil is in use for individuals with ovarian cancer and is undergoing clinical trials for use in various stages of ovarian and other advanced women's cancers. The therapy shows promise for applications in multiple solid tumor types.
Clinical Trials for Vigil
Gradalis is actively conducting clinical trials for their personalized cancer immunotherapy, Vigil. These trials focus on various stages of ovarian cancer and other advanced women's cancers. The goal is to evaluate the safety and efficacy of Vigil and to expand its potential applications across a spectrum of solid tumor types. Gradalis' clinical trials are essential for advancing their innovative approach to cancer treatment.